Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor
Open accessAbstract
Testicular germ cell tumor (GCT) is the most common malignancy in young males between the ages of 15 to 35 years. Although the overall cure rate of GCTs approaches 95%, almost 25% of patients with distant metastases die from the cancer. Active investigations on novel treatment options for platinum-refractory GCTs include immunotherapies such as program-death 1 (PD-1)/program death-ligand 1 (PD-L1) inhibitors. In this case, we report a patient with metastatic GCTs who was treated with pembrolizumab, a PD-L1 inhibitor, in a phase II study after failing several lines of chemotherapy. We highlighted the rationale for the use of PD-L1 inhibitor in this population.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a case report of a patient with cisplatin-refractory metastatic choriocarcinoma, pembrolizumab was administered and the tumor progressed rapidly soon after starting immunotherapy, leading to early discontinuation of ICI.
“In another case report of a patient with cisplatin-refractory metastatic choriocarcinoma, pembrolizumab was administered. However, the patient’s tumor progressed rapidly soon after starting immunotherapy, leading to the early discontinuation of the ICI [49].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Frequent PD-L1 Expression in Testicular Germ Cell Tumors
Fankhauser, C. D., Curioni-Fontecedro, A., Allmann, V, Beyer, J., Tischler, V, Sulser, T., Moch, H., & Bode, P. K. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.244 · Cited by 174 · see citing works
Cierna, Z., Mego, M., Miskovska, V., Machalekova, K., Chovanec, M., Svetlovska, D., Hainova, K., Rejlekova, K., Macak, D., Spanik, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv574 · Cited by 162 · see citing works
Treatment of growing teratoma syndrome
Vaughn, D. J., Flaherty, K., Lal, P., Gallagher, M., O'Dwyer, P., Wilner, K., Chen, I., & Schwartz, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808558 · Cited by 82 · see citing works
Flagged first, then by citations
Research works printed but not linked: 18
- [2]Motzer RJ Escudier B McDermott DF Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803- 13. 26406148 PMC5719487
- [3]Garon EB Rizvi NA Hui R Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018- 28. 25891174
- [4]Robert C Long GV Brady B Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320- 30. 25399552
- [6]International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 152: 594- 603. 9053482
- [7]Nichols CR Catalano PJ Crawford ED Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998; 16: 1287- 93. 9552027
- [8]Pico JL Rosti G Kramar A A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16: 1152- 9. 15928070
- [9]Lorch A Bascoul-Mollevi C Kramar A Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178- 84. 21444870
- [10]Lorch A Kleinhans A Kramar A Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): six-year long-term follow-up of a prospective, randomized phase II trial. ASCO Meet Abstr 2011; 29: 4507.
- [11]Einhorn LH Williams SD Chamness A High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357: 340- 8. 17652649
- [12]Feldman DR Sheinfeld J Bajorin DF TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28: 1706- 13. 20194867 PMC3651604
- [13]Pectasides D Pectasides M Farmakis D Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004; 15: 493- 7. 14998855
- [14]Robert C Schachter J Long GV Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372: 2521- 32. 25891173
- [15]Herbst RS Baas P Kim DW Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540- 50. 26712084
- [17]Bagrodia A Kaffenberger SD Lee B Actionable targets in patients with cisplatin-resistant advanced germ cell tumors. J Clin Oncol 2016; 34: 473. PMC5477828 27646943
- [18]Houldsworth J Reuter V Bosl GJ Chaganti RS Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Differ Mol Biol J Am Assoc Cancer Res 1997; 8: 293- 9. 9056671
- [19]Skotheim RI Abeler VM Nesland JM Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays. Neoplasia N Y N 2003; 5: 397- 404. PMC1502610 14670177
- [20]Dickson MA Schwartz GK Development of cell-cycle inhibitors for cancer therapy. Curr Oncol Tor Ont 2009; 16: 36- 43. PMC2669234 19370178
- [21]Schwartz GK Lo Russo PM Dickson MA Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 2011; 104: 1862- 8. 21610706 PMC3111206
Cited by
Sorted by citations
Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J. (2024) · Cancers · doi:10.3390/cancers16020428 · Cited by 11 · see citing works
“However, the patient’s tumor progressed rapidly soon after starting immunotherapy, leading to the early discontinuation of the ICI [49].”
Background
- Authors
- Loh, K. P., & Fung, C.
- Affiliations
- Strong Memorial Hospital (US)
- Corresponding author
- Loh, Kah Poh
- Venue
- Rare Tumors
- Publisher
- SAGE Publications
- Published
- 2017-08-01
- Volume
- 9
- Issue
- 2
- Pages
- 47-49
- ISSN
- 2036-3605 (ISSN-L)
- 2036-3613
- PMC
- PMC5617913
- OpenAlex
- W2730097746
- Cited by
- 23
- References
- 3
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 3 · 2022: 3 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 1
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Rare Tumors (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Surgery › Testicular diseases and treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- testicular germ cell tumors, metastatic germ cell tumors, platinum-refractory disease, PD-1 inhibitors, pembrolizumab, PD-L1 blockade, immune checkpoint inhibitors, immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
